Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00393276 · ClinicalTrials.gov registry record · Phase 1
Determining Responses to Two Different Vaccines in HIV and HCV Infected Individuals
A Phase 1 study of HIV Infections and Hepatitis C, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 1
- Development phase
- 29
- Enrollment target
- 12
- Study locations
NCT00393276 is a Phase 1 study of HIV Infections and Hepatitis C that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 29 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (93% lower). The trial reports 12 study locations across 9 states.
The verdict
NCT00393276, a Phase 1 study of HIV Infections and Hepatitis C, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 29 participants
- Enrollment target
- 12
- Study locations
Study Summary
Infection with either HIV or hepatitis C virus (HCV) affects immune system responses. The purpose of this study is to investigate the immune responses to two different vaccine formulations in HIV-infected, HCV-infected, and HCV/HIV- coinfected individuals.
Conditions Studied
Interventions
- BIOLOGICAL Twinrix
- BIOLOGICAL Decavac
Study Locations (12)
Ohio
- Case CRS - Cleveland
- MetroHealth CRS - Cleveland
- The Ohio State University Medical Center - Columbus
California
- UCSD Antiviral Research Center CRS - San Diego
- Ucsf Aids Crs - San Francisco
Colorado
- University of Colorado Hospital CRS - Aurora
Maryland
- IHV Baltimore Treatment CRS - Baltimore
Massachusetts
- Massachusetts General Hospital Clinical Research Site (MGH CRS) CRS - Boston
New York
- Columbia P&S CRS - New York
North Carolina
- Duke Univ. Med. Ctr. Adult CRS - Durham
Texas
- Trinity Health and Wellness Center CRS - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2007-08 |
| Est. Completion | 2009-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00393276
The ClinicalTrials.gov registry entry for NCT00393276 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (93% lower). The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with HIV Infections appearing as the primary indexed condition, and to 2 interventions - of which Twinrix is the first listed.
NCT00393276 reports 12 study locations spanning 9 distinct geographic areas - top geographies include Ohio, California, Colorado.
Frequently Asked Questions
What is clinical trial NCT00393276 about?
NCT00393276 is a clinical study titled "Determining Responses to Two Different Vaccines in HIV and HCV Infected Individuals". Infection with either HIV or hepatitis C virus (HCV) affects immune system responses. The purpose of this study is to investigate the immune responses to two different vaccine formulations in HIV-infected, HCV-infected, and HCV/HIV- coinfected individuals.
What is the current status of trial NCT00393276?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 2007-08. Estimated completion is 2009-07.
What conditions does trial NCT00393276 study?
This clinical trial studies the following conditions: HIV Infections, Hepatitis C.
What interventions are being tested in trial NCT00393276?
The interventions under investigation include: Twinrix (BIOLOGICAL), Decavac (BIOLOGICAL).
Who is sponsoring clinical trial NCT00393276?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00393276 being conducted?
This trial has 12 study locations across California, Colorado, Maryland, Massachusetts, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
CAR-T Cells for HIV Infection
RECRUITING · Phase 1
-
A Study to Investigate the Use of VH3810109 With or Without Fostemsavir (FTR) to Reduce the Size and Activity of the Viral Reservoir in People Living With HIV
RECRUITING · Phase 1
-
Clinical Trial to Evaluate the Safety and Immunogenicity of Hiltonol, Poly-ICLC-adjuvanted CD40.HIVRI.Env (VRIPRO) in Adult Participants Who Previously Participated in HVTN 706
RECRUITING · Phase 1
-
Pharmacokinetics, Safety, Tolerability of Dolutegravir/Rilpivirine in Pediatrics
RECRUITING · Phase 1
-
A Study to Investigate Pharmacokinetics, Safety and Tolerability of Long-Acting Cabotegravir Plus Recombinant Human Hyaluronidase PH20 in Healthy Adult Participants
RECRUITING · Phase 1
-
First Time in Human Study of Long Acting VH4524184 Formulations
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.